Who is at the highest risk? 3 points each – Cancer – Prior VTE – Hypercoagulability 2 points – Major surgery 1 point each – Age >70 – Obesity (BMI >29)

Slides:



Advertisements
Similar presentations
IDEAL 1 and IDEAL 2.
Advertisements

Special Article Adolescent Overweight and Future Adult Coronary Heart Disease Kirsten Bibbins-Domingo, Ph.D., M.D., Pamela Coxson, Ph.D., Mark J. Pletcher,
Derivation of analytic sample. ED indicates erectile dysfuntion; MEC, Mobile Examination Center Christopher S. Saigal, et al, Arch Intern Med. 2005;166:
Prevalence of Obesity* among U.S. Adults BRFSS, 2000 Source: Mokdad A H, et al. J Am Med Assoc 2000;284:13 No Data
Recent advances in Radiotherapy of CNS Tumours Dr Vivek Bansal Director, Dept of Radiation Oncology HCG Cancer Centre,Sola Ahmedabad,Gujarat,India .
Outpatient treatment of pulmonary embolism
Statin Landmark Trials Across the Spectrum of Risk: Secondary CV Prevention.
A GRADUATING RESEARCH PROJECT FOR THE BACHALOLIC DEGEES.
Time line of data collection in the Nurses’ Health Study, 1988 to 2000 A. Heather Eliassen et al, Arch Intern Med. 2005; 165:
The Health Roundtable 3-3c_HRT1215-Session_HANNAFORD_UNSW_NSW How many people received appropriate VTE prophylaxis? Presenter: Natalie Hannaford UNSW Innovation.
Derivation and Validation of a Prediction Tool for Venous Thromboembolism (VTE): A VERITY Registry Study Roopen Arya, Shankaranarayana Paneesha, Aidan.
 Incidence rate (symptomatic): 1%  ½ occur after discharge  We don’t understand which patients are at highest risk.
The DASH Study Patrick Leonberger MSIV BGSMC Nov 8, 2013.
1 Background Hypertension Type 2 diabetes Coronary heart disease Gallbladder disease Certain cancers Dyslipidemia Stroke Osteoarthritis Sleep apnea Approximately.
S urgical P re A dmission R eview C linics (SPARC) Truc Nguyen Pharmacy Surgical Team Leader CMH Pharmacy.
 Data review  Risk factors and prevention  Secondary prevention.
Uncontrolled Hypertension, Systolic and Diastolic Blood Pressure and Development of Symptomatic Peripheral Arterial Disease in the Women’s Health Study.
CURE: Prior Stroke or TIA OutcomeC + ASAASAHRP value MI/stroke/ CV death 49/274 (17.9%)52/232 (22.4)0.74 (0.50, 1.10)0.13 Non-CABG TIMI major bleeding.
HEALTHY EATING And LIVING Kenneth E. Nixon MD. Problem Overweight and Obesity 97 million adults are overweight or obese Medical Problems Associated with.
Evaluating the Performance of a Previously Reported Risk Score to Predict Venous Thromboembolism: A VERITY Registry Study Denise O'Shaughnessy, Peter Rose,
Frank B. Hu et al N Engl J Med 2004; 351: Body-Mass Index and Relative Risk of Death from All Causes during 24 Years of Follow-up.
Clinical Utility of BRCA Testing Mark Robson, MD September 7,
Relationships, interpersonal skills & social support.
Risk assessment for VTE
TEMPLATE DESIGN © Objectives To compare the outcome in patients with one previous scar between those who had a spontaneous.
Preventing Hospital Acquired Thrombosis Simon Noble Peggy Edwards.
Antiplatelet Therapy Use and the Risk of Venous Thromboembolic Events in the Double-Blind Raloxifene Use for the Heart (RUTH) Trial C. Duvernoy 1, A. Yeo.
Zacho J, et al. N Engl J Med 2008;359: Risk of Ischemic Heart Disease as a Function of Plasma Levels of C-Reactive Protein (CRP) in the General.
Nearly 5 Million Americans Have CHF 400,000 new onset cases diagnosed annually 1400,000 new onset cases diagnosed annually 1 Over 250,000 deaths annually.
Pai JK et al. N Engl J Med 2004; 351: Relative CHD risk by increasing baseline CRP plasma levels,* relative to CRP
Impact of early surgery vs conventional treatment for infective endocarditis on mortality and embolic events: data from EASE trial Prospective RCT ( );
Venous Thromboembolism Prophylaxis for Medical Inpatients Heather Hofmann, rev. 4/18/14 DSR2 Mini Lecture.
Chapter Seven Venous Disease Coalition Long-Term Management of VTE VTE Toolkit.
PSA Testing Importance of Multiple Markers Ian Thompson MD Department of Urology University of Texas HSC San Antonio, TX.
Lars Sjöström et al N Engl J Med 2004; 351: Characteristics of the Subjects at the Time of Matching and at the Time of the Inclusion Examination.
Demographic Characteristics of the Study Population - Part I Jenny N.Poynter et al N Engl J Med 2005;352:
DVT & PE: How early can I mobilize a patient ??
Solomon Tesfaye et al N Engl J Med 2005;352: Comparison of Baseline Data in 1819 Patients According to Whether There Was an Assessment for Neuropathy.
Risk assessment for VTE Dr Roopen Arya King’s College Hospital.
Clinical predictors of adverse outcome in VTE outpatients – the VERITY PUSH (Prospective Follow-Up Survey in Verity Hospitals) study Peter Rose, Aidan.
Risk Assessment for VTE. Which of the following best describes you?
Exercise and adult women’s health Amos Pines. Exercise improves cardiovascular risk profile Body mass index Total, abdominal (subcutaneous and visceral)
Retinopathy in Youth With Type 2 Diabetes Participating in the TODAY Clinical Trial Featured Article: TODAY Study Group* Diabetes Care Volume 36:
Slide Source: Lipids Online Slide Library C-Reactive Protein, Metabolic Syndrome, and Risk for CV Events: Women’s Health Study 14,719.
Distribution of metabolic syndrome (MS) components by age and gender Zhao D, et al. Am J Cardiol 2007;100:835– 839.
Bariatric Surgery for T2DM The STAMPEDE Trial. A.R. BMI 36.5 T2DM diagnosed age 24 On Metformin, glyburide  insulin Parents with T2DM, father on dialysis.
Spotlight Case January 2006 An Ounce of Prevention.
Venous Thromboembolism Prophylaxis for Medical Inpatients
Obesity Trends* Among U.S. Adults BRFSS, 1985
Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.
Muhammad Shahreyar et al. JACEP 2016;j.jacep
LEVO-CTS Trial design: Patients undergoing cardiac surgery with the use of cardiopulmonary bypass were randomized to infusion of levosimendan 0.2 µg/kg/min.
Diet, Obesity, and Chronic Disease
אביבה אלקלעי, ראש היחידה לכניסה להוראה, המכללה האקדמית אחווה
מהו הסטאז'? המכללה האקדמית תלפיות.
Measure Acute rejection Chronic allograft nephropathy
Cystatin C levels and risk of death from all causes
Risk for BMI outcome (%)
Enrollment and Outcomes
Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,
Baseline Characteristics of the Subjects
William T. Abraham et al. JCHF 2015;3:
Baseline Characteristics of the Study Participants
Age-Standardized Rates of Death from Any Cause According to the Estimated GFR among 1,120,295 Ambulatory Adults Alan S.Go et al. N Engl J Med 2004; 351:
Characteristics of Participants in the Nurses Health Study According to Alcohol Intake Meir J.Stampfer et al N Engl J Med 2005;352:
Baseline Characteristics of Elderly Participants in the Cardiovascular Health Study,According to Quintiles of Cystatin C Michael G.Shlipak et al N Engl.
Long-term risk for ever being overweight or more or obese
A Single Participant Exposed Twice to an Inflammatory Stimulus
Fig. 1: Relative risks of death from any cause among participants with various risk factors (e.g., history of hypertension, chronic obstructive pulmonary.
Two to 20 years: female patients, continued.
Presentation transcript:

Who is at the highest risk? 3 points each – Cancer – Prior VTE – Hypercoagulability 2 points – Major surgery 1 point each – Age >70 – Obesity (BMI >29) – Bed rest – HRT or COC Increased risk >4 points at any time point after admission Kucher, N. et al. N Engl J Med 2005;352:

Simplified PESI Retrospective analysis of RIETE registry – Age >801 p –History of Cancer 1 p –Chron cardiopulmonary dis.1 p –Pulse >110 1 p –CHF1 p –SBP <100 1 p –SaO 2 <90%1 p 0 = low risk, 1 or more = high risk Jiménez D et al. Arch Intern Med. 2010;170:1383-9

Summary Diagnostic Rules PESI/sPESI most validated – 7 items HESTIA more complex – 11 items ESC is minimalistic, although requires asessment of RV dysfunction, perhaps more dependent on how the physician assesses

Acute treatment algorithm Hemodynamic Instability (shock) t-PA Large PE But stable Heparin IV  LMWH Submassive PE Rivaroxaban 15 mg bid  20 mg q.d. Vitamin K antagonist LMWH therap dose  cancer

Rivaroxaban - Important to know Starting dose 15 mg BID Switch after 3 weeks to 20 mg daily Must be taken with food Tablets contain lactose (some get stomach pain) Severe renal failure (CrCl <30 mL/min) or concomitant ketokonazole or other azoles, rifampicin and ritonavir are contraindications Few of the study patients hade extensive DVT or large PE. These patients might benefit from intial parenteral Rx.